Scienture (NASDAQ: SCNX) is a clinical-stage biotechnology company specializing in the discovery and development of novel small-molecule therapeutics. Founded in 2014 and headquartered in Boston, Massachusetts, the company integrates artificial intelligence, machine learning and high-throughput screening technologies through its proprietary platform, NeuroCatalyst. This platform is designed to streamline the identification of lead compounds across multiple therapeutic areas, enabling more efficient transitions from discovery to preclinical and clinical stages.
The company’s R&D pipeline targets oncology, immunology and neurodegenerative diseases, with lead programs advancing in early-phase trials. In oncology, Scienture is exploring precision therapies that selectively target tumor-specific pathways. In neurodegeneration, the firm’s AI-driven models aim to identify candidate molecules that modulate protein misfolding and neuronal survival. Complementing its internal efforts, Scienture offers contract research services and licensing agreements to biopharmaceutical partners seeking to leverage its computational platform for focused drug discovery projects.
Scienture maintains strategic collaborations with academic institutions and pharmaceutical companies across North America, Europe and Asia. Its global footprint includes R&D centers in Cambridge, U.K., and Tokyo, Japan, alongside partnerships that facilitate access to specialized screening facilities and regional clinical trial networks. These alliances support the company’s goal of delivering breakthrough therapies to a diverse patient population while sharing risk and expertise with established industry players.
Under the leadership of CEO Dr. Amelia Reyes, a veteran of biotech research and development, Scienture’s management team combines deep experience in drug discovery, regulatory affairs and business development. The board comprises industry experts in genomics, pharmacology and medical affairs, positioning the company to drive its AI-enabled pipeline toward regulatory milestones and potential commercialization.
AI Generated. May Contain Errors.
